About Boston Scientific Corporation
https://www.bostonscientific.comBoston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular.
CEO
Michael F. Mahoney
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2003-11-06 | Forward | 2:1 |
| 1998-12-01 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 850
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 17
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:145.18M
Value:$13.61B
VANGUARD GROUP INC
Shares:138.25M
Value:$12.96B
BLACKROCK INC.
Shares:126.42M
Value:$11.85B
Summary
Showing Top 3 of 2,112
About Boston Scientific Corporation
https://www.bostonscientific.comBoston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $5.07B ▲ | $2.49B ▼ | $755M ▼ | 14.91% ▼ | $0.51 ▼ | $1.03B ▼ |
| Q2-2025 | $5.06B ▲ | $2.6B ▲ | $793M ▲ | 15.67% ▲ | $0.54 ▲ | $1.37B ▲ |
| Q1-2025 | $4.66B ▲ | $2.05B ▼ | $674M ▲ | 14.45% ▲ | $0.46 ▲ | $1.22B ▲ |
| Q4-2024 | $4.56B ▲ | $2.08B ▲ | $566M ▲ | 12.41% ▲ | $0.38 ▲ | $1.07B ▲ |
| Q3-2024 | $4.21B | $1.97B | $469M | 11.14% | $0.32 | $1.06B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $534M ▼ | $41.56B ▲ | $18.91B ▲ | $22.42B ▲ |
| Q1-2025 | $725M ▲ | $40.14B ▲ | $17.69B ▲ | $22.21B ▲ |
| Q4-2024 | $414M ▼ | $39.4B ▲ | $17.39B ▲ | $21.77B ▲ |
| Q3-2024 | $2.5B ▼ | $38.08B ▲ | $17.12B ▲ | $20.71B ▲ |
| Q2-2024 | $2.91B | $37.11B | $16.5B | $20.37B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $795M ▲ | $1.29B ▲ | $-1.13B ▼ | $-340M ▼ | $-178M ▼ | $1.1B ▲ |
| Q1-2025 | $672M ▲ | $541M ▼ | $-500M ▲ | $233M ▲ | $313M ▲ | $354M ▼ |
| Q4-2024 | $562M ▼ | $1.46B ▲ | $-3.7B ▼ | $214M ▲ | $-2.04B ▼ | $1.16B ▲ |
| Q3-2024 | $700M ▲ | $1B ▲ | $-1.43B ▼ | $7M ▼ | $-413M ▼ | $698M ▲ |
| Q2-2024 | $324M | $813M | $-271M | $24M | $566M | $658M |
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Cardiovascular | $2.73Bn ▲ | $2.94Bn ▲ | $3.08Bn ▲ | $3.35Bn ▲ |
 MedSurg | $1.48Bn ▲ | $1.62Bn ▲ | $1.58Bn ▼ | $1.72Bn ▲ |
Revenue by Geography
| Region | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 NonUS | $1.62Bn ▲ | $1.67Bn ▲ | $1.70Bn ▲ | $1.84Bn ▲ |
 UNITED STATES | $2.59Bn ▲ | $2.89Bn ▲ | $2.96Bn ▲ | $2.04Bn ▼ |
CEO
Michael F. Mahoney
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2003-11-06 | Forward | 2:1 |
| 1998-12-01 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 850
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 17
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:145.18M
Value:$13.61B
VANGUARD GROUP INC
Shares:138.25M
Value:$12.96B
BLACKROCK INC.
Shares:126.42M
Value:$11.85B
Summary
Showing Top 3 of 2,112